First Recently-diagnosed Colorectal CancerAGARICNCT01966081
AGARIC Case Control Study
A study testing Blood sample and tissue samples from abdominal subcutaneous adipose in people with First Recently-diagnosed Colorectal Cancer, run by Centre Hospitalier Universitaire Dijon at 5 sites in France.
Trial summary
The aim of the study is to establish the existence of a relationship between the dietary intake of polyunsaturated fatty acids (PUFA) and the risk of colorectal cancer in humans, using 2 reliable and complementary biomarkers: the fatty acid-composition of lipids of the abdominal subcutaneous adipose tissue and the… Read more about this study
- Who is it for?
- Ages 45 years and older
- Conditions the study is for
- First Recently-diagnosed Colorectal Cancer
- What is being tested?
- Blood sample and tissue samples from abdominal subcutaneous adipose
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 551 participants
- Where
- 5 sitesFrance
- Study dates
- 15 Sep 2008to 15 Jun 2011
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 years and older
- All sexes
- Adult, Older adult
Who may be able to join
- CASES
- Patients aged ≥ 45 years
- with a first recently-diagnosed colorectal cancer
- due to undergo elective surgical resection with curative intent (in practice, stage I, II, III or IV if there was only one hepatic nodule that was resected with curative intent) in one of the 5 following digestive surgery units: CHU de Dijon, CHU de Nancy, CHU de Strasbourg, CHU de Reims et CHU and Besançon.
- who have given their informed consent
- CONTROLS
Show all 10Show fewer
- Patients aged ≥ 45 years
- due to undergo surgery for a benign abdominal disease (sigmoid diverticulitis, appendectomy, hiatal hernia …)
- matched for abdominal site with cases for age (± 3 years), sex and hospital
- Who have given their informed consent
Who cannot join
- CASES
- pre-operative anticancer treatment (chemo or radiotherapy)
- existence of visceral metastases except a single hepatic nodule resected with curative intent
- familial adenomatous polyposis and HNPCC syndrome (when suspected: inclusion after complementary tumor phenotype study: screening for microsatellite instability and/or immunohistochemistry study of the expression of DNA mismatch repair proteins.
- known inflammatory disease of the intestine (ulcerative colitis, Crohn's disease)
- personal history (recent or not) of colorectal cancer
Show all 21Show fewer
- emergency treatment for the presenting complication (perforation, occlusion…)
- significant modification in dietary habits during the previous three months
- other evolving neoplastic disease
- psychic state incompatible with understanding the modalities and the aims of the study (notably patients under guardianship)
- pregnant or breast-feeding women
- CONTROLS
- personal history of cancer or adenomatous colorectal polyps,
- emergency intervention
- known inflammatory disease of the intestine (ulcerative colitis, Crohn's disease)
- personal history (recent or not) of colorectal cancer
- emergency treatment for the presenting complication (perforation, occlusion…)
- significant modification in dietary habits during the previous three months
- evolving neoplastic disease
- psychic state incompatible with understanding the modalities and the aims of the study (notably patients under guardianship)
- pregnant or breast-feeding women
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
France5 sites
CHU Jean Minjoz
Besançon, 25030
CHU Dijon
Dijon, 21079
Hôpital Robert Debré
Reims, 51092
Hôpital Hautepierre
Strasbourg, 67200
Hôpital de BRABOIS
Vandœuvre-lès-Nancy, 54511
About this study
Official title: Consumption of Fatty Acids, Metabolism of Adipose Tissue and Risk of Colorectal Cancer: AGARIC Case Control Study
The aim of the study is to establish the existence of a relationship between the dietary intake of polyunsaturated fatty acids (PUFA) and the risk of colorectal cancer in humans, using 2 reliable and complementary biomarkers: the fatty acid-composition of lipids of the abdominal subcutaneous adipose tissue and the fatty acid composition of erythrocyte phospholipids.
- Being tested
- Blood sample, tissue samples from abdominal subcutaneous adipose
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood sampleOther
tissue samples from abdominal subcutaneous adiposeOther
| Study group | Role | What they receive |
|---|---|---|
| Cases | Other | Not described Receives: Other: Blood sample; Other: tissue samples from abdominal subcutaneous adipose |
| controls | Other | Not described Receives: Other: Blood sample; Other: tissue samples from abdominal subcutaneous adipose |
What is being measured
The primary outcome is the main question the study is designed to answer.
Measure of polyunsaturated fatty acids in adipose tissue lipids.
Measured: baselines
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Oct 2013 (estimated)
- Study start15 Sep 2008
- Primary completion15 Jun 2011
- Study completion15 Jun 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for First Recently-diagnosed Colorectal CancerStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire DijonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Enrolment
- 551 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire Dijon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01966081
- Sponsor's protocol ID
- Bonithon hors AOI 2008
- Acronym
- AGARIC
- Status last verified
- Feb 2026
- First submitted
- 10 Oct 2013
- Last updated
- 9 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
Publications
Cottet V, Vaysse C, Scherrer ML, Ortega-Deballon P, Lakkis Z, Delhorme JB, Deguelte-Lardiere S, Combe N, Bonithon-Kopp C. Fatty acid composition of adipose tissue and colorectal cancer: a case-control study. Am J Clin Nutr. 2015 Jan;101(1):192-201. doi: 10.3945/ajcn.114.088948. Epub 2014 Nov 12.
PubMed 25527763
Study at a glance
From the registry record, last updated by the sponsor on 9 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Consumption of Fatty Acids, Metabolism of Adipose Tissue and Risk of Colorectal Cancer: AGARIC Case Control Study
- ClinicalTrials.gov ID
- NCT01966081
- Acronym / sponsor ID
- AGARIC / Bonithon hors AOI 2008
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 551 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire DijonUniversity, hospital or other
- Study start
- 15 Sep 2008 (actual)
- Primary completion
- 15 Jun 2011 (actual)
- Study completion
- 15 Jun 2011 (actual)
- First posted
- 21 Oct 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to establish the existence of a relationship between the dietary intake of polyunsaturated fatty acids (PUFA) and the risk of colorectal cancer in humans, using 2 reliable and complementary biomarkers: the fatty acid-composition of lipids of the abdominal subcutaneous adipose tissue and the fatty acid composition of erythrocyte phospholipids.
Study design
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cases | Other | Other: Blood sample, Other: tissue samples from abdominal subcutaneous adipose |
| controls | Other | Other: Blood sample, Other: tissue samples from abdominal subcutaneous adipose |
Who may qualify
- Ages
- 45 years and older
- Sex
- All
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- CASES
- Patients aged ≥ 45 years
- with a first recently-diagnosed colorectal cancer
- due to undergo elective surgical resection with curative intent (in practice, stage I, II, III or IV if there was only one hepatic nodule that was resected with curative intent) in one of the 5 following digestive surgery units: CHU de Dijon, CHU de Nancy, CHU de Strasbourg, CHU de Reims et CHU and Besançon.
- who have given their informed consent
Key exclusion criteria (21 listed)
- CASES
- pre-operative anticancer treatment (chemo or radiotherapy)
- existence of visceral metastases except a single hepatic nodule resected with curative intent
- familial adenomatous polyposis and HNPCC syndrome (when suspected: inclusion after complementary tumor phenotype study: screening for microsatellite instability and/or immunohistochemistry study of the expression of DNA mismatch repair proteins.
- known inflammatory disease of the intestine (ulcerative colitis, Crohn's disease)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood sample | Other | Cases, controls |
| tissue samples from abdominal subcutaneous adipose | Other | Cases, controls |
Primary outcome
Measure of polyunsaturated fatty acids in adipose tissue lipids.
Time frame: baselines
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Feb 2026.
- Results publication: PubMed 25527763Cottet V, Vaysse C, Scherrer ML, Ortega-Deballon P, Lakkis Z, Delhorme JB, Deguelte-Lardiere S, Combe N, Bonithon-Kopp C. Fatty acid composition of adipose tissue and colorectal cancer: a case-control study. Am J Clin Nutr. 2015 Jan;101(1):192-201. doi: 10.3945/ajcn.114.088948. Epub 2014 Nov 12.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Blood sample and tissue samples from abdominal subcutaneous adipose in people with First Recently-diagnosed Colorectal Cancer, run by Centre Hospitalier Universitaire Dijon at 5 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Measure of polyunsaturated fatty acids in adipose tissue lipids. (time frame: baselines). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01966081, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2026.